(Q54369245)

28 May 2018

meta-analysis

0 references

title

Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis. (English)

1 reference

28 May 2018

author name string

Zhijun Li

1

1 reference

28 May 2018

Yongjun Zhang

2

1 reference

28 May 2018

Wenlong Bao

3

1 reference

28 May 2018

Chuming Jiang

4

1 reference

28 May 2018

publication date

14 March 2014

1 reference

28 May 2018

published in

Targeted oncology

1 reference

28 May 2018

volume

9

1 reference

28 May 2018

page(s)

381-388

1 reference

28 May 2018

issue

4

1 reference

28 May 2018

https://scigraph.springernature.com/pub.10.1007/s11523-014-0312-2

exact match

0 references

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Quantification of free circulating DNA as a diagnostic marker in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0312-2

The biology of epidermal growth factor receptor in lung cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24623059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24623059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24623059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-014-0312-2

1 reference

28 May 2018

PubMed ID

24623059

1 reference

28 May 2018